Marlanka A. Zuur - Publications

Quality Assessment of Dried Blood Spots from Patients With Tuberculosis from 4 Countries.

Journal: Therapeutic drug monitoring

Published: June 07, 2019

Cost-utility analysis of high-dose treatment for intermediate-susceptible, dose-dependent tuberculosis patients.

Journal: The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease

Published: August 11, 2018

Evaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant Mycobacterium tuberculosis.

Journal: Antimicrobial agents and chemotherapy

Published: July 17, 2018

Intermediate Susceptibility Dose-Dependent Breakpoints For High-Dose Rifampin, Isoniazid, and Pyrazinamide Treatment in Multidrug-Resistant Tuberculosis Programs.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: November 08, 2017

Pharmacokinetics of 2,000 Milligram Ertapenem in Tuberculosis Patients.

Journal: Antimicrobial agents and chemotherapy

Published: November 02, 2017

Pharmacokinetic Modeling and Limited Sampling Strategies Based on Healthy Volunteers for Monitoring of Ertapenem in Patients with Multidrug-Resistant Tuberculosis.

Journal: Antimicrobial agents and chemotherapy

Published: September 13, 2016

Fixed-dose combination and therapeutic drug monitoring in tuberculosis: friend or foe?

Journal: The European respiratory journal

Published: April 27, 2016

Dried blood spots can help decrease the burden on patients dually infected with multidrug-resistant tuberculosis and HIV.

Journal: The European respiratory journal

Published: March 23, 2016

Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis.

Journal: Expert opinion on drug metabolism & toxicology

Published: March 08, 2016